How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

16,978 results for

HIV Course

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

181. BHIVA guidelines on the management of opportunistic infection in people living with HIV: The clinical management of gastrointestinal opportunistic infections

on the management of opportunistic infection in people living with HIV: The clinical management of Candidiasis 2019. HIV Med 2019; 20 Suppl 8: 2–24. 5. Kadayifci A, Gulsen MT, Koruk M, Savas MC. Doxycycline-induced pill esophagitis. Dis Esophagus 2004; 17: 168–171. 6. Wilcox CM, Alexander LN, Clark WS, Thompson SE. Fluconazole compared with endoscopy for human immunodeficiency virus-infected patients with esophageal symptoms. Gastroenterology 1996; 110: 1803–1809. 7. Onishi A, Iwasaku M, Sato A, Furukawa TA (...) in HIV-infected patients in the era of highly active antiretroviral therapy and an increasing trend of fluoroquinolone resistance. Clin Infect Dis 2007; 45: e60–67. 53. Hung CC, Chang SC. Impact of highly active antiretroviral therapy on incidence and management of human immunodeficiency virus-related opportunistic infections. J Antimicrob Chemother 2004; 54: 849–853. 54. B-Lajoie MR, Drouin O, Bartlett G et al. Incidence and prevalence of opportunistic and other infections and the impact

2020 British HIV Association

182. BHIVA/BASHH/BIA Adult HIV Testing guidelines

-transmissions-by-2030 (accessed November 2019). 3. Walensky RP, Weinstein MC, Kimmel AD et al. Routine human immunodeficiency virus testing: an economic evaluation of current guidelines. Am J Med 2005; 118: 292–300. 4. Graves N, Walker DG, McDonald AM et al. Would universal antenatal screening for HIV infection be cost-effective in a setting of very low prevalence? Modelling the data for Australia. J Infect Dis 2004; 190: 166–174. 5. General Medical Council. Consent: patients and doctors making decisions (...) public health impact of non-targeted human immunodeficiency virus screening in 29 emergency departments. Arch Intern Med 2012; 172: 12–20. 64. De Coster DA, Sivalokanathan S, Sornum A, Kegg S. HIV testing of acute medical admissions – any sign of progress? HIV Med 2015; 16 Suppl 2: 12–77 (Abstract P148). 65. Cropp A. Is the acute medical unit (AMU) the right place for HIV testing? A real life look. HIV Med 2015; 16 Suppl 2: 12–77 (Abstract P147). 66. Elgalib A, Fidler S, Sabapathy K. Hospital-based

2020 British HIV Association

183. Characteristics, Prevention, and Management of Cardiovascular Disease in People Living With HIV: A Scientific Statement From the American Heart Association

Pathophysiology in HIV: Metabolic Contributors HIV infection is associated with metabolic complications, including dyslipidemia, insulin resistance, and body composition changes, which can contribute to CVD. Initially, dyslipidemia in HIV was characterized by increased triglyceride levels, thought to be related to immunodeficiency in the pre-ART era. Later, specific ART medications, including several protease inhibitors (PIs) and efavirenz, a non–nucleoside reverse transcriptase inhibitor (NRTI), were (...) Characteristics, Prevention, and Management of Cardiovascular Disease in People Living With HIV: A Scientific Statement From the American Heart Association Characteristics, Prevention, and Management of Cardiovascular Disease in People Living With HIV: A Scientific Statement From the American Heart Association | Circulation Search Hello Guest! Login to your account Email Password Keep me logged in Search December 2019 November 2019 October 2019 September 2019 August 2019 July 2019 June 2019 May

2019 American Heart Association

184. Long-term Effects of Chemoradiotherapy for Anal Cancer in Patients With HIV Infection: Oncological Outcomes, Immunological Status, and the Clinical Course of the HIV Disease. (Abstract)

Long-term Effects of Chemoradiotherapy for Anal Cancer in Patients With HIV Infection: Oncological Outcomes, Immunological Status, and the Clinical Course of the HIV Disease. Despite the increasing evidence for chemoradiotherapy as standard treatment for anal cancer in patients with HIV infection, there is still some uncertainty regarding increased toxicity and adverse effects on the immune status.We report the clinical outcome of 5-fluorouracil/mitomycin C-based concurrent chemoradiotherapy (...) for anal carcinoma in patients with HIV infection with an emphasis on the long-term course of CD4 counts and the HIV-related morbidity during follow-up.A retrospective single-institution chart review was performed.Between 1997 and 2012, 36 HIV-positive patients were treated with standard chemoradiotherapy (median tumor dose, 54 (range, 50.4-60.4) Gy at 1.8 Gy/fraction; 5-fluorouracil, 800-1000 mg/m(2), days 1-4 or 1-5; mitomycin C, 10 mg/m(2), day 1, in the first and fifth week).A retrospective

2014 Diseases of the Colon & Rectum

185. Looking upstream to prevent HIV transmission: can interventions with sex workers alter the course of HIV epidemics in Africa as they did in Asia? (Abstract)

Looking upstream to prevent HIV transmission: can interventions with sex workers alter the course of HIV epidemics in Africa as they did in Asia? High rates of partner change in 'upstream' sex work networks have long been recognized to drive 'downstream' transmission of sexually transmitted infections (STIs). We used a stochastic microsimulation model (STDSIM) to explore such transmission dynamics in a generalized African HIV epidemic.We refined the quantification of sex work in Kisumu, Kenya (...) , from the 4-cities study. Interventions with sex workers were introduced in 2000 and epidemics projected to 2020. We estimated the contribution of sex work to transmission, and modelled standard condom and STI interventions for three groups of sex workers at feasible rates of use and coverage.Removing transmission from sex work altogether would have resulted in 66% lower HIV incidence (range 54-75%) and 56% lower prevalence (range 44-63%) after 20 years. More feasible interventions reduced HIV

2014 AIDS

186. The Effect of Vitamin C, Thiamine and Hydrocortisone on Clinical Course and Outcome in Patients With Severe Sepsis and Septic Shock

The Effect of Vitamin C, Thiamine and Hydrocortisone on Clinical Course and Outcome in Patients With Severe Sepsis and Septic Shock The Effect of Vitamin C, Thiamine and Hydrocortisone on Clinical Course and Outcome in Patients With Severe Sepsis and Septic Shock - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have (...) reached the maximum number of saved studies (100). Please remove one or more studies before adding more. The Effect of Vitamin C, Thiamine and Hydrocortisone on Clinical Course and Outcome in Patients With Severe Sepsis and Septic Shock The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT03335124

2017 Clinical Trials

187. Higher Transplacental Pathogen-Specific Antibody Transfer Among Pregnant Women Randomized to Triple Antiretroviral Treatment Versus Short Course Zidovudine. Full Text available with Trip Pro

Higher Transplacental Pathogen-Specific Antibody Transfer Among Pregnant Women Randomized to Triple Antiretroviral Treatment Versus Short Course Zidovudine. HIV-1 infection may impair transplacental antibody transfer to infants. The impact of highly active antiretroviral treatment (ART) given during pregnancy on transplacental antibody transport is unknown.HIV-1 infected pregnant women with CD4 counts between 200 - 500 were randomized to short-course zidovudine (ZDV) or triple ART at 32 weeks (...) gestation for prevention of mother-to-child HIV-1 transmission. Levels of maternal antibody against measles, pneumococcus and rotavirus at delivery, and antibody transfer to the baby through cord blood, were compared between trial arms.Overall, 141 and 148 women were randomized to triple ART and ZDV, respectively; cord blood was available for a subset (n = 20 in triple ART and n = 22 in ZDV). Maternal antibody levels to all pathogens during pregnancy and at delivery were not significantly different

2017 Pediatric Infectious Dsease Journal

188. Short Course of Postoperative Hepatitis B Immunoglobulin Plus Antivirals Prevents Reinfection of Liver Transplant Recipients. (Abstract)

(in hospital only) HBIG in liver transplant recipients with HBV DNA less than 100 IU/mL pre-LT.A total of 42 hepatitis B surface antigen (HBsAg) positive, human immunodeficiency virus and hepatitis D virus-negative patients with pretransplant HBV DNA undetectable to 100 IU/mL who received HBIG 5000 IU in anhepatic phase and daily for 5 days together with nucleos(t)ide analogues indefinitely yielded 1- and 3-year cumulative incidences of recurrence, defined by positive serum HBsAg, of 2.9% (upper 95 (...) Short Course of Postoperative Hepatitis B Immunoglobulin Plus Antivirals Prevents Reinfection of Liver Transplant Recipients. Hepatitis B immune globulin (HBIG) has been an integral component of prophylaxis against hepatitis B virus (HBV) recurrence in liver transplantation (LT) recipients, but HBIG is costly and inconvenient to administer, prompting consideration of alternative regimens.In this retrospective cohort, we report on the success of antiviral therapy combined with a short course

2017 Transplantation

189. Nivolumab, Ipilimumab, and Short-course Radiotherapy in Adults With Newly Diagnosed, MGMT Unmethylated Glioblastoma

of anaphylaxis, or uncontrolled asthma (that is, 3 or more features of partially controlled asthma). Unable tolerate an MRI, or have a contraindication to MRI. Active infection requiring systemic therapy. Known history of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome. Positive test for hepatitis B virus surface antigen (HBV sAg) or hepatitis C virus (HCV antibody) indicating acute or chronic infection. Vaccination within 4 weeks of the first dose of study (...) Nivolumab, Ipilimumab, and Short-course Radiotherapy in Adults With Newly Diagnosed, MGMT Unmethylated Glioblastoma Nivolumab, Ipilimumab, and Short-course Radiotherapy in Adults With Newly Diagnosed, MGMT Unmethylated Glioblastoma - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number

2017 Clinical Trials

190. A Biosignature Predicting Complicated Course in Children Presenting with Septic Shock. Why PERSEVERE? Full Text available with Trip Pro

A Biosignature Predicting Complicated Course in Children Presenting with Septic Shock. Why PERSEVERE? 28809515 2017 12 13 2018 12 02 1535-4970 196 4 2017 08 15 American journal of respiratory and critical care medicine Am. J. Respir. Crit. Care Med. A Biosignature Predicting Complicated Course in Children Presenting with Septic Shock. Why PERSEVERE? 411-413 10.1164/rccm.201704-0759ED Randolph Adrienne G AG 0000-0002-3084-3071 1 Department of Anesthesiology, Perioperative and Pain Medicine (...) ppublish 28809515 10.1164/rccm.201704-0759ED PMC5564677 PLoS One. 2014 Mar 13;9(3):e92121 24626215 Clin Pharmacol Ther. 2001 Mar;69(3):89-95 11240971 PLoS One. 2014 Jan 29;9(1):e86242 24489704 Crit Care Med. 2016 Nov;44(11):2010-2017 27513537 Crit Care Med. 1996 May;24(5):743-52 8706448 Expert Opin Med Diagn. 2013 Jan;7(1):37-51 23335946 Crit Care Med. 2013 Jul;41(7):1761-73 23685639 Pediatr Crit Care Med. 2005 Jan;6(1):2-8 15636651 Crit Care. 2012 Oct 01;16(5):R174 23025259 Curr Opin HIV AIDS. 2010

2017 American Journal of Respiratory and Critical Care Medicine

191. Time-course, negative-stain electron microscopy–based analysis for investigating protein–protein interactions at the single-molecule level Full Text available with Trip Pro

and potentially capture states that are unobservable with ensemble methods because they are below the limit of detection or not conducted on an appropriate time scale. Using the HIV-1 envelope glycoprotein (Env) and its interaction with receptor CD4-binding site neutralizing antibodies as a model system, we both corroborate ensemble kinetics-derived parameters and demonstrate how time-course EM can further dissect stoichiometric states of complexes that are not readily observable with other methods (...) Time-course, negative-stain electron microscopy–based analysis for investigating protein–protein interactions at the single-molecule level Several biophysical approaches are available to study protein-protein interactions. Most approaches are conducted in bulk solution, and are therefore limited to an average measurement of the ensemble of molecular interactions. Here, we show how single-particle EM can enrich our understanding of protein-protein interactions at the single-molecule level

2017 The Journal of biological chemistry

192. Short Course Regimens for Treatment of PKDL (Sudan)

Short Course Regimens for Treatment of PKDL (Sudan) Short Course Regimens for Treatment of PKDL (Sudan) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Short Course Regimens for Treatment of PKDL (Sudan (...) -existing clinical hearing loss based on audiometry at baseline Patients with a positive HIV test as applicable Patients / guardian not willing to participate Patients with history of allergy or hypersensitivity to the relevant study drug Patients on immunomodulators therapy Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please

2017 Clinical Trials

193. An Open Study to Assess the Safety and Pharmacokinetics of Fluorothyazinone as a Single-Dose Administration or a Treatment Course in Healthy Volunteers

An Open Study to Assess the Safety and Pharmacokinetics of Fluorothyazinone as a Single-Dose Administration or a Treatment Course in Healthy Volunteers An Open Study to Assess the Safety and Pharmacokinetics of Fluorothyazinone as a Single-Dose Administration or a Treatment Course in Healthy Volunteers - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved (...) Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. An Open Study to Assess the Safety and Pharmacokinetics of Fluorothyazinone as a Single-Dose Administration or a Treatment Course in Healthy Volunteers The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our

2017 Clinical Trials

194. Emtricitabine/tenofovir alafenamide (HIV) - Addendum to Commission A16-30

and Laboratory Abnormalities“. h: Effect estimate and 95 % CI not meaningfully interpretable. i: SOC. j: HLGT and SMQ. AE: adverse event; AIDS: acquired immunodeficiency syndrome; CDC: Centers for Disease Control and Prevention; CI: confidence interval; COBI: cobicistat; CSR: clinical study report; CSZ: convexity, symmetry, z score; EVG: elvitegravir; FDA: Food and Drug Administration; FTC: emtricitabine; HIV-1: human immunodeficiency virus type 1, HLGT: High Level Group Term; M = E: missing = excluded; M =F (...) and listings [unpublished]. 2016. 6. Martín Andrés A, Silva Mato A. Choosing the optimal unconditioned test for comparing two independent proportions. Computat Stat Data Anal 1994; 17(5): 555-574. 7. Food and Drug Administration. Guidance for industry: human immunodeficiency virus-1 infection; developing antiretroviral drugs for treatment [online]. 11.2015 [Accessed: 13.07.2016]. URL: http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/UCM355128.pdf. 8. Food and Drug

2017 Institute for Quality and Efficiency in Healthcare (IQWiG)

195. Canadian guideline on HIV pre-exposure prophylaxis and nonoccupational postexposure prophylaxis

of initiation and dura- tion of treatment. J Virol 1998;72:4265-73. 26. Wade NA, Birkhead GS, Warren BL, et al. Abbreviated regimens of zidovudine pro- phylaxis and perinatal transmission of the human immunodeficiency virus. N Engl J Med 1998;339:1409-14. 27. Mayer KH, Mimiaga MJ, Gelman M, et al. Raltegravir, tenofovir DF, and emtric- itabine for postexposure prophylaxis to prevent the sexual transmission of HIV: safety, tolerability, and adherence. J Acquir Immune Defic Syndr 2012;59:354-9. 28 (...) -generation antibody/antigen combo assay. Those with signs or symptoms of acute HIV should also undergo HIV RNA or pooled nucleic acid amplification test. †Hepatitis A and/or B vaccine should be initiated in unvaccinated individuals. Those who remain nonimmune to hepatitis B virus should be rescreened annually. ‡Individuals with chronic active hepatitis B should be managed in consultation with an expert on hepatitis B virus according to Canadian guidelines. §Individuals who have STIs should be offered

2017 CPG Infobase

196. CIHR Canadian HIV Trials Network Co-Infection and Concurrent Diseases Core: Canadian guidelines for management and treatment of HIV/hepatitis C coinfection in adults

Annual CAHR Conference (Vancouver, British Columbia). introduction Continued improvements in combination antiretroviral therapy (ART) have resulted in sustained gains in projected life expectancy for HIV-infected individuals (1). Long-term management of HIV now increasingly requires assessment and appropriate interventions for comorbid conditions that may impact long-term morbidity and mor- tality to a greater extent than HIV infection itself. Mortality second- ary to chronic hepatitis C virus (HCV (...) of these recommendations can be found on page 231. speCIal aRTICle ©2013 Pulsus Group Inc. All rights reserved m Hull, m Klein, s s hafran, et al; on behalf of t he ci Hr c anadian HiV t rials n etwork HiV/Hepatitis c management and t reatment Guidelines Working Group. ciHr canadian HiV t rials n etwork c oinfection and c oncurrent d iseases core: canadian guidelines for management and treatment of HiV/hepatitis c coinfection in adults. c an J infect d is med microbiol 2013;24(4):217-238. BacKGround: Hepatitis C virus

2014 CPG Infobase

197. Public health guidance on antenatal screening for HIV, hepatitis B, syphilis and rubella susceptibility in the EU/EEA ? addressing the vulnerable populations

susceptibility in the EU/EEA SCIENTIFIC ADVICE iv Abbreviations ANS Antenatal screening CRS Congenital rubella syndrome HBsAg Hepatitis B surface antigen HBV Hepatitis B virus HIV Human immunodeficiency virus MMR Measles, mumps, rubella vaccine MTCT Mother-to-child transmission PICO (T) Population, intervention, comparison, outcome, time PWID People who inject drugs STI Sexually transmitted infection TESSy The European Surveillance System WHO World Health Organization SCIENTIFIC ADVICE Antenatal screening (...) Public health guidance on antenatal screening for HIV, hepatitis B, syphilis and rubella susceptibility in the EU/EEA ? addressing the vulnerable populations SCIENTIFIC ADVICE Antenatal screening for HIV, hepatitis B, syphilis and rubella susceptibility in the EU/EEA – addressing the vulnerable populations www.ecdc.europa.euECDC SCIENTIFIC ADVICE Antenatal screening for HIV, hepatitis B, syphilis and rubella susceptibility in the EU/EEA – addressing the vulnerable populations ii This report

2017 European Centre for Disease Prevention and Control - Public Health Guidance

198. BHIVA/BASHH guidelines on the use of HIV pre-exposure prophylaxis (PrEP)

was a secondary outcome. At interim review, the DSMB recommended that all study participants should be offered study drug. A total of 23 participants became infected with HIV over the course of the study: three in the daily TDF-FTC group and 20 in the deferred (no-PrEP) group, representing a rate difference in HIV infection of 7.8 per 100 person-years (90% CI 4.3–11.3) The relative risk reduction was 86% (90% CI 64–96%) and the number needed to treat over 1 year to prevent one HIV infection was 13 (90% CI 9 (...) ceasing sexual risk. Participants were followed up every 8 weeks for HIV testing and risk-reduction advice, and every 6 months for sexually transmitted infection (STI) testing for a total of 431 person-years of follow-up. Primary endpoint was HIV infection. At interim review, the placebo group was discontinued and all study participants were offered study drug. Over the course of the study, 16 people became infected with HIV: two in the TDF-FTC group and 14 in the placebo group, representing

2018 British Association for Sexual Health and HIV

199. HIV Pre-Exposure Prophylaxis with Emtricitabine/Tenofovir Disoproxil Fumarate — Regulatory and Reimbursement Policies

be effectively treated with a range of antiretroviral drugs as part of antiretroviral therapy (ART) to suppress the virus and halt its progression. ART also reduces the transmission of the virus. 3 However, at this time a permanent cure remains elusive and much focus is given to prevention. Until recently, the main approaches to HIV infection prevention consisted of promoting the use of physical barriers during sex (condoms) or behavioural changes such as needle exchange when injecting drugs and avoidance (...) of high-risk sexual encounters — precautions that may not be accepted by some individuals. This situation changed in 2012 with the FDA approval and availability of the fixed-dose antiviral combination emtricitabine and tenofovir disoproxil fumarate (FTC/TDF) Truvada, manufactured by Gilead, for HIV pre-exposure prophylaxis (PrEP) in the US. Taking the antivirals once daily lowers the likelihood of HIV establishing a productive infection in the human host. 4 Clinical trials have shown this treatment

2017 Canadian Agency for Drugs and Technologies in Health - Environmental Scanning

200. HIV Pre-Exposure Prophylaxis with Emtricitabine/Tenofovir Disoproxil Fumarate — Regulatory and Reimbursement Policies

be effectively treated with a range of antiretroviral drugs as part of antiretroviral therapy (ART) to suppress the virus and halt its progression. ART also reduces the transmission of the virus. 3 However, at this time a permanent cure remains elusive and much focus is given to prevention. Until recently, the main approaches to HIV infection prevention consisted of promoting the use of physical barriers during sex (condoms) or behavioural changes such as needle exchange when injecting drugs and avoidance (...) of high-risk sexual encounters — precautions that may not be accepted by some individuals. This situation changed in 2012 with the FDA approval and availability of the fixed-dose antiviral combination emtricitabine and tenofovir disoproxil fumarate (FTC/TDF) Truvada, manufactured by Gilead, for HIV pre-exposure prophylaxis (PrEP) in the US. Taking the antivirals once daily lowers the likelihood of HIV establishing a productive infection in the human host. 4 Clinical trials have shown this treatment

2017 Canadian Agency for Drugs and Technologies in Health - Environmental Scanning

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>